Selected research publications
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19 A Dose-Escalating, Randomized Controlled Phase Ib Study – Journal: Clinical Pharmacology and Therapeutics – Published: 18th March 2026
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5′-triphosphate (T-705-RTP) in human peripheral mononuclear cells. – Journal: Journal of Pharmaceutical and Biomedical Analysis – Published: 21st April 2024
Therapeutics for treating mpox in humans – Journal: Cochrane Database of Systematic Reviews – Published: 14th March 2023
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. – Journal: The Lancet Infectious Diseases – Published: 1st February 2023
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2 – Journal: Clinical Pharmacology and Therapeutics – Published: 26th October 2021
View more publications